Apogee Therapeutics (APGE): 18-month performance

Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.

• IPO: July 14, 2023
• The company priced its upsized IPO (initially filed for ~15.6 million shares) on July 13, 2023, at $17.00 per share, raising approximately $300 million. 
• https://www.apogeetherapeutics.com 

1 month later:

Clinical Pipeline Progress (2026)

• Zumilokibart (Lead Asset): Apogee announced highly successful 16-week Part B induction data from its Phase 2 APEX trial treating moderate-to-severe atopic dermatitis (eczema). 
• Phase 3 Launch: Backed by the positive Phase 2 findings, the mid-dose configuration of zumilokibart is scheduled to enter Phase 3 clinical trials in 2H 2026.
• Indication Expansion: Capitalizing on a "pipeline-in-a-product" framework, Apogee is initiating Phase 2 trials for eosinophilic esophagitis (EoE) in late 2026 and asthma trials in 1H 2027.